Identifying the culprit lesion in tumor induced hypophosphatemia, the solution of a clinical enigma
Open Access
- 5 October 2016
- journal article
- case report
- Published by Springer Science and Business Media LLC in Endocrine
- Vol. 54 (3), 642-647
- https://doi.org/10.1007/s12020-016-1092-5
Abstract
No abstract availableThis publication has 24 references indexed in Scilit:
- Tumor localization and biochemical response to cure in tumor-induced osteomalaciaJournal of Bone and Mineral Research, 2013
- Tumor-induced osteomalacia: An important cause of adult-onset hypophosphatemic osteomalacia in China: Report of 39 cases and review of the literatureJournal of Bone and Mineral Research, 2012
- Tumor-induced osteomalaciaEndocrine-Related Cancer, 2011
- Selective venous catheterization for the localization of phosphaturic mesenchymal tumorsJournal of Bone and Mineral Research, 2010
- Medication-induced hypophosphatemia: a reviewQJM: An International Journal of Medicine, 2010
- Fibroblast growth factor 23 impairs phosphorus and vitamin D metabolism in vivo and suppresses 25-hydroxyvitamin D-1α-hydroxylase expression in vitroAmerican Journal of Physiology-Renal Physiology, 2007
- Hypophosphatemia: an evidence-based approach to its clinical consequences and managementNature Clinical Practice Nephrology, 2006
- Fibroblast growth factor 23 reduces expression of type IIa Na+/Pi co‐transporter by signaling through a receptor functionally distinct from the known FGFRs in opossum kidney cellsGenes to Cells, 2005
- Review and Update: Oncogenic Osteomalacia-RicketsUltrastructural Pathology, 1991
- Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or ricketsCancer, 1987